- Home
- EGY vs CRVS Comparison
EGY vs CRVS Comparison
Compare EGY & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EGY
- CRVS
- Stock Information
- Founded
- EGY 1985
- CRVS 2014
- Country
- EGY United States
- CRVS United States
- Employees
- EGY N/A
- CRVS N/A
- Industry
- EGY Oil & Gas Production
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- EGY Energy
- CRVS Health Care
- Exchange
- EGY Nasdaq
- CRVS Nasdaq
- Market Cap
- EGY 389.8M
- CRVS 305.4M
- IPO Year
- EGY N/A
- CRVS 2016
- Fundamental
- Price
- EGY $3.65
- CRVS $4.17
- Analyst Decision
- EGY
- CRVS Strong Buy
- Analyst Count
- EGY 0
- CRVS 4
- Target Price
- EGY N/A
- CRVS $15.00
- AVG Volume (30 Days)
- EGY 915.0K
- CRVS 1.0M
- Earning Date
- EGY 08-05-2025
- CRVS 08-05-2025
- Dividend Yield
- EGY 6.86%
- CRVS N/A
- EPS Growth
- EGY N/A
- CRVS N/A
- EPS
- EGY 0.56
- CRVS N/A
- Revenue
- EGY $489,162,000.00
- CRVS N/A
- Revenue This Year
- EGY N/A
- CRVS N/A
- Revenue Next Year
- EGY $24.62
- CRVS N/A
- P/E Ratio
- EGY $6.55
- CRVS N/A
- Revenue Growth
- EGY 3.02
- CRVS N/A
- 52 Week Low
- EGY $3.00
- CRVS $1.96
- 52 Week High
- EGY $7.43
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- EGY 51.95
- CRVS 53.38
- Support Level
- EGY $3.73
- CRVS $4.08
- Resistance Level
- EGY $3.94
- CRVS $4.31
- Average True Range (ATR)
- EGY 0.13
- CRVS 0.25
- MACD
- EGY -0.01
- CRVS 0.01
- Stochastic Oscillator
- EGY 50.00
- CRVS 68.66
About EGY VAALCO Energy Inc.
VAALCO Energy Inc is an independent energy company operating in the United States. It is principally engaged in the acquisition, exploration, development, and production of crude oil and natural gas. The company operates through geographical segments namely Gabon, Egypt, Canada, Equatorial Guinea, and Cote d'Ivoire. The company generates maximum revenue from the Gabon segment.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).